Cargando…
Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)
Osteopenia and osteoporosis have increasingly become a recognized morbidity in those persons with hemophilia (PwH) receiving inadequate prophylactic clotting factor replacement. Animal models can control or eliminate genetic and environmental factors and allow for invasive testing not clinically per...
Autores principales: | Larson, Emily A., Larson, Hillary J., Taylor, Jason A., Klein, Robert F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484143/ https://www.ncbi.nlm.nih.gov/pubmed/34117910 http://dx.doi.org/10.1007/s00223-021-00872-x |
Ejemplares similares
-
Coagulation Factor IX for Hemophilia B Therapy
por: Orlova, N. A., et al.
Publicado: (2012) -
Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019) -
Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021) -
CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
por: Guan, Yuting, et al.
Publicado: (2016) -
Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)